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Drug-induced liver injury (DILI) is a known adverse effect of both anti-tuberculosis
(anti-TB) and antiretroviral (ARV) drugs. Recent studies highlight the implications
of genetic predispositions to DILI. We performed a case-control study to identify
Human Leukocyte Antigen-B (HLA-B) variant alleles associated with anti-TB and ARV
co-treatment induced liver toxicity in Ethiopian TB and HIV co-infected patients. A total
of 495 newly diagnosed TB and HIV co-infected patients were enrolled and received
rifampicin based anti-TB and efavirenz based ARV therapy. Change in liver enzyme level
from baseline was monitored 1st, 2nd, 4th, 8th, 12th, and 24th weeks after treatment
initiation to identify patients who developed DILI (cases) and those who did not (treatment
tolerants). Genomic DNA from 46 cases and 46 sex and agematched treatment tolerants
were genotyped for HLA-B variant alleles using Olerup SSP®HLA-B DNA Typing Kits.
The proportion of HLA-B∗57 allele carriers in DILI cases (37.0%), particularly in those
who developed cholestatic type of DILI (44.8%) was significantly higher compared
with those who tolerated the treatment (2.2%). The HLA-B∗57 allele frequency was
significantly higher in cases (25%) than treatment tolerants (1.1%). In amultivariate logistic
analysis, the proportion of patients carrying HLA-B∗57 (P = 0.002) and HLA-B∗14 (P =
0.014) alleles were significantly higher in DILI cases compared with treatment tolerants.
HLA-B∗57 was significantly associated with cholestatic (P = 0.001) and mixed (P =
0.017) types of liver toxicity, and mild-to-moderate severity (P = 0.001). Of all HLA-
B∗57 alleles detected, HLA-B∗57:03 accounted 58.3% and HLA-B∗57:02 accounted
41.7%. HLA-B∗57:01 was not detected. The variant allele frequencies of HLA-B∗57:03
(15.2 vs. 0%) and HLA-B∗57:02 (9.8 vs. 1.1%) were significantly higher in the DILI cases
than treatment tolerants (P < 0.03). We conclude that HLA-B∗57 alleles (B∗57:03 and
B∗57:02) confer susceptibility to the development of anti-TB and ARV drugs co-treatment
induced liver toxicity, which is mainly of cholestatic type. The possible association ofHLA-
B∗14 with anti-TB and ARV drugs co-treatment induced liver toxicity requires further
investigations.
Keywords: antiretroviral drugs, anti-tuberculosis, drug induced hepatotoxicity, DILI, Ethiopian, HIV, HLA,
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INTRODUCTION
Tuberculosis (TB) is the most common opportunistic infection
associated with human immunodeficiency virus (HIV) infection,
and co-treatment of the two diseases is recommended (Harries
et al., 2009). However, simultaneous treatment of TB and HIV
infections is challenging due to drug interactions and overlapping
toxicities (Cohen and Meintjes, 2010). Antiretroviral (ARV) and
anti-tuberculosis (anti-TB) Drugs-induced liver injury (DILI)
is a common adverse event, which can be fatal if therapy
is not interrupted or changed on time (Devarbhavi et al.,
2013; Naidoo et al., 2015; Shamanna et al., 2016). TB-HIV
co-infected patients on anti-TB and ARV co-therapy are at a
higher risk of developing DILI than TB or HIV only infected
patients receiving monotherapy (Yimer et al., 2011, 2014;
Mugusi et al., 2012). A recent study in TB/HIV patients on
anti-TB and antiretroviral therapy (ART) with high levels of
immune activation demonstrated impaired isoniazid clearance,
implicating the need for exploring immune response and the risk
of DILI (Vinnard et al., 2016). Up to 32% of HIV patients on ART
discontinue their treatment or switch therapy mainly due to DILI
(Bica et al., 2001), and genetic predisposition contributes partly
(Lubomirov et al., 2011). Treatment interruption may increase
the risk for developing of multidrug-resistant TB (MDR-TB) and
HIV/AIDS (Hirpa et al., 2013). Thus, identifying genetic markers
for drug-induced liver toxicity is valuable to identify high-risk
patients and to introduce appropriate measures.
Both HIV and TB remain a major problem and co-infection is
common in most Sub-Saharan African (SSA) countries including
Ethiopia, the second most densely populated country in Africa
with an estimated population size of 100 million. Ethiopia is
listed among the top 20 high-TB burden countries globally, and
one of the high MDR-TB burden countries (Biadglegne et al.,
2014; World-Health-Organization, 2016). The rate of new HIV
infection in Ethiopia is declining with the estimated number of
people living with HIV being 769, 600 in 2014 (World-Health-
Organization1). The scale of ART is increasing in the country as
part achieving the UNAID/WHO “90-90-90” target: to diagnose
90% of all HIV positive people, provide ART for 90% of those
diagnosed and achieve viral suppression for 90% of those treated,
by 2020 (UNAIDS, 2014). ART and anti-TB drug-induced liver
toxicity is a common problem in Ethiopia causing treatment
discontinuation and hence MDR-TB (Hirpa et al., 2013; Yimer
et al., 2014).
Genetic variations in HLA gene is implicated with
susceptibility to T-cell mediated adverse events to a wide
range of pharmaceuticals making it a candidate gene relevant
to pharmacogenetic studies (Barbarino et al., 2015). HLA
alleles that are reported to be association with increased risk
of idiosyncratic DILI include: HLA-DQB1∗02:01 and DQB1∗05
to anti-TB drugs (Sharma et al., 2002; Chen et al., 2015), and
HLA-B∗58:01 and DRB1∗01:02 to nevirapine-containing ARV
regimens (Phillips et al., 2013).HLA-B∗57:01 andA∗33:03 variant
alleles were also reported as genetic markers for idiosyncratic
1World Health Organization. Ethiopia. HIV/AIDS. Available online at: http://
www.afro.who.int/en/ethiopia/country-programmes/topics/4480-hivaids.html
(Accessed January 29, 2017).
liver injury induced by flucloxacillin (Daly et al., 2009) and
ticlopidine (Hirata et al., 2008) respectively. Susceptibility to
amoxicillin-clavulanate-induced liver injury is influenced by
multiple HLA class I and II alleles (Lucena et al., 2011). A large
genome-wide association study found a strong association of
amoxicillin-clavulanate induced liver injury with HLA-A∗02:01,
HLA-DQB1∗06:02, and DRB1∗15:01 variant alleles (Lucena
et al., 2011). Genetic screening for HLA-B∗57:01 and subsequent
treatment modifications have been shown to reduce incidence
of life-threatening hypersensitivity to abacavir in HIV/AIDS
patients carrying the allele (Hughes et al., 2008; Mallal et al.,
2008) and HLA-B∗15:02 to carbamazepine in Southeast Asian
carriers (Amstutz et al., 2014).
Most previous reports investigating genetic risk factors for
anti-TB and ARV drugs-induced liver toxicity focused on drug
metabolizing enzymes and transporter proteins (Lee et al., 2010;
Yimer et al., 2011, 2012). Previously we reported the association
of high efavirenz plasma concentration and CYP2B6∗6 genotype
with DILI in TB-HIV patients (Yimer et al., 2011, 2012; Mugusi
et al., 2012). However, only a few studies have explored the
association of HLA genes with anti-TB or ARV drugs-induced
liver toxicity. Therefore, in this study, we aimed to investigate
the possible associations between HLA-B alleles, and anti-TB and
ARV drugs co-treatment induced liver injury in TB and HIV
co-infected patients in Ethiopia.
METHODS
Study Design and Participants
Using a case-control comparative study design, we analyzed
data from newly diagnosed TB and HIV co-infected patients,
who were enrolled and followed up prospectively to identify the
incidence, the pattern, and severity of anti-TB and ARV drugs-
induced liver toxicity in Ethiopian patients (Yimer et al., 2014).
In brief, 495 TB and HIV co-infected patients with CD4 count
≤200 cells/mm3 were recruited from three health institutions:
Kazanchis and Beletshachew health centers, and Tikur Anbessa
Specialized Hospital in Addis Ababa, Ethiopia, from June 2007 to
June 2012. The inclusion criteria were TB and HIV co-infected
men and non-pregnant women with age 18 years old and above.
Patients were excluded if they had a history of prior treatment for
TB/HIV or known pre-existing liver disease.
The study protocol was approved by the Institutional Review
Board of College of Health Sciences, Addis Ababa University,
the National Research Ethics Review Committee of Ethiopia, and
Ethical Review Board of Karolinska Institutet, Sweden. Written
informed consent was obtained from all the study participants in
accordance with the Declaration of Helsinki.
Drug Treatment
All the study participants received first line ARV drugs
containing efavirenz and lamivudine with tenofovir, zidovudine,
or stavudine. A short-course anti-TB regimen consisting of
rifampicin, isoniazid, pyrazinamide, and ethambutol for the
first 2 months followed by rifampicin and isoniazid for the
next 4 months was given. The patients did not receive other
known hepatotoxic drugs concurrently, except co-trimoxazole
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prophylaxis that was given for TB and HIV co-infected patients
according to the National Treatment Guideline. Change in liver
enzymes levels from baseline was monitored on the 1st, 2nd, 4th,
8th, 12th, and 24th weeks after initiation of treatment.
Case Definitions, Severity Grade, and
Pattern of Liver Toxicity
The criteria set by the International DILI Expert Working
Group were used for DILI case definitions and pattern of liver
injury determination (Aithal et al., 2011). The upper limit of
normal (ULN) for liver enzymes used for the study population
were alanine aminotransferase (ALT 33 U/L for male; 29 U/L
for female), aspartate aminotransferase (AST, 41 U/L), alkaline
phosphatase (ALP, 128 U/L), and 1.0 mg/dL for total bilirubin
(Yimer et al., 2014). All cases recruited met at least one of the
following criteria: (1) ALT ≥ 5xULN, (2) ALP ≥ 2xULN, or
(3) ALT ≥ 3xULN along with total bilirubin (T Bil) ≥ 2xULN.
Treatment tolerants (controls) were individuals who were on
anti-TB and ARV drugs co-treatment but did not fulfill the case
definitions for DILI and had not presented with clinical signs and
symptoms consistent with DILI in the follow-up period.
The pattern of liver toxicity was defined using R-value,
where R = (ALT/ULN)/(ALP/ULN). Cases were categorized as
hepatocellular (R ≥ 5), cholestatic (R ≤ 2), or mixed (2 < R
< 5) pattern of DILI. Clinical severity grading was determined
by employing the highest measured values for each of the
biochemical parameters (Yimer et al., 2014). Patients with grades
one and two severities were grouped together into a “mild-to-
moderate” group and those with grades three and four into a
“severe” group. Causality assessment for DILI was performed
using Roussel Uclaf Causality Assessment Method (RUCAM;
Danan and Benichou, 1993).
Among the 495 TB and HIV co-infected patients involved
in the initial cohort, 120 experienced DILI in the follow-up
period (Yimer et al., 2014). Of these, 80 cases and 275 treatment
tolerants had adequate DNA available for further analysis. After
excluding patients that had abnormal liver biochemistry prior to
starting treatment, or patients who had serological test positive
for either hepatitis B virus surface antigen or anti-hepatitis C
virus antibody, 46 cases and 46 treatment tolerants that have
complete clinical data and matched with respect to gender and
age in a 1:1 ratio were used for the current study.
HLA-B Genotyping
Genomic DNA was isolated from peripheral blood using
QIAamp DNA Maxi Kit (QIAGEN GmbH. Hilden. Germany).
We first screened for HLA-B variant alleles using a low-
resolution (two digits) genotyping. HLA-B genotyping was
performed using low-resolution Olerup SSP R©HLA-B Typing
Kit (Olerup SSP AB, Franzengatan 5, SE-112 51 Stockholm,
Sweden). Allele-specific polymerase chain reaction (PCR), using
sequence-specific primers was done according to the protocol
and recommendations of the manufacturer. The amplified PCR
products were analyzed using 2% agarose gel, and the HLA-
B allele types were determined using HELMBERG-SCORE
software. Low-resolution typing results were recorded with the
2-digit code to ensure a uniform level of HLA resolution for the
alleles.
As a next step, high resolution (four digits) typing were done
for HLA-B variant alleles that showed significant association
with DILI based on the low-resolution genotyping data. HLA-
B∗57 exhibited a significant association with DILI, and high-
resolution subtyping was performed for all HLA-B∗57 allele
carriers using Olerup SSP R©HLA-B∗57:01Typing Kit (Olerup SSP
AB, Franzengatan5, SE-112 51 Stockholm, Sweden) according to
the protocol and recommendations of the manufacturer.
Statistical Analysis
Continuous variables were presented by a mean and standard
deviation, and categorical variables as numbers and percentages.
Univariate logistic regression analysis was used to identify
potential independent risk factors for anti-TB and ARV drugs
co-treatment induced liver toxicity. Variables with P < 0.1 in
the univariate analysis were included in a multivariate logistic
analysis. The strength of the associations was estimated by
calculating the odds ratio (OR) and 95% confidence interval (CI).
Fisher’s exact test was used for HLA-B alleles with <5 expected
cell count in a 2 × 2 table. To reduce bias in estimating the
OR, Haldane’s modification was employed (Haldane, 1956) i.e.,
whenever a zero-count cell was encountered, 0.5 was added to
all cells in the 2 × 2 table. P < 0.05 were considered statistically
significant. The corrected P-values (Pc) were adjusted by using
Bonferroni’s correction for multiple comparisons (18 tests) to
account for the number of HLA-B alleles observed in the study
participants. The statistical analysis was performed using IBM
SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk,
NY, USA).
RESULTS
A total of 92 TB and HIV co-infected patients on anti-TB
and ARV drugs co-treatment were involved in this study; 46
treatment induced liver toxicity cases and 46 sex and age
matched treatment tolerants. The demographics and clinical
characteristics of the study participants are described in Table 1.
In the univariate analysis, there were statistically significant
differences in the CD4 count and Karnofsky score between DILI
cases and treatment tolerants (P< 0.05). In a multivariate logistic
analysis, baseline CD4 count remained as significant predictors
of anti-TB and ARV drugs co-treatment induced liver injury.
There were no statistically significant differences in the baseline
liver enzyme levels and type of ARV regimens used between the
DILI cases and treatment tolerants. More than half of the DILI
cases developed the cholestatic type of liver toxicity, and 85% of
the cases had mild-to-moderate severity of liver toxicity. All of
the cases had a minimum score of three (“possible”) in RUCAM
scoring system for DILI.
HLA-B genotype result from the low resolution typing for
each study participant is presented in Supplementary Table
1. Comparison of HLA-B allele carriers’ proportions between
patients who developed DILI vs. treatment tolerants is presented
in Table 2. A total of 18 HLA-B variant alleles were detected
(Table 2). In the univariate analysis, the proportion ofHLA-B∗57
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TABLE 1 | Demographics and clinical characteristics of the study participants.
Characteristics Cases Treatment tolerants Univariate analysis Multivariate analysis
(N = 46) (N = 46) P OR (95% CI) P OR (95% CI)
Sex (M/F) 22/24 22/24 1.00 1.00 (0.44–2.27)
Age (yrs), mean (SD) 35.4 (9.3) 35.3 (8.7) 0.95 0.99 (0.95–1.05)
BMI (kg/m2), mean (SD) 18.4 (2.4) 19.1 (3.5) 0.25 1.09 (0.94–1.26)
CD4 count (per mm3 ), mean (SD) 69.3 (48.7) 94.2 (51.4) 0.02 1.01 (1.01–1.02) 0.03 1.01 (1.00-1.02)
Viral load (copies/ml), log mean (SD) 5.3 (1.0) 5.0 (1.0) 0.20 0.72 (0.44–1.19)
Karnofsky score 82.8 (13.6) 88.7 (13.4) 0.04 1.03 (1.00–1.07) 0.06 1.03 (0.99–1.07)
LFT VALUES, MEAN (SD)
Baseline ALT (U/L) 25.5 (9.8) 27.8 (8.3) 0.22 1.03 (0.98–1.08)
Baseline AST (U/L) 32.7 (10.3) 31.9 (9.6) 0.70 0.99 (0.95–1.03)
Baseline ALP (U/L) 99.5 (19.3) 104.3 (19.3) 0.23 1.01 (0.99–1.04)
Baseline TBil (mg/dL) 0.7 (0.5) 0.7 (0.4) 0.71 0.84 (0.34–2.10)
ARV REGIMEN, N (%)
TDF/3TC/EFV 15 (32.6) 12 (26.1) 0.49 1.37 (0.56–3.38)
ZDV/3TC/EFV 16 (34.8) 16 (34.8) 1.00 1.00 (0.42–2.36)
D4T/3TC/EFV 15 (32.6) 18 (39.1) 0.52 0.75 (0.32–1.78)




SEVERITY GRADE, N (%)
Mild-to-moderate 39 (84.8)
Severe 7 (15.2)
RUCAM SCALE, N (%)
Definite (score > 8) 30 (65.2)
Probable (score 6–8) 12 (26.1)
Possible (score 3–5) 4 (8.7)
3TC, Lamivudine; ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; ARV, Antiretroviral; AST, Aspartate aminotransferase; BMI, Body mass index; CI, Confidence Interval; D4T,
Stavudine; EFV, Efavirenz; HIV, Human immunodeficiency virus; LFT, Liver function test; OR, Odds ratio; RUCAM, Roussel Uclaf Causality Assessment Method; SD, Standard deviation;
T Bil, Total bilirubin; TB, Tuberculosis; TDF, Tenofovir; ZDV, Zidovudine. P-value < 0.05 is highlighted in bold.
and HLA-B∗14 alleles carriers were significantly higher in DILI
cases than treatment tolerants. Association of being a carrier of
HLA-B∗57 with increased risk for DILI remained significant after
correction formultiple testing. On the other hand,HLA-B∗41was
negatively associated with DILI. The multivariate logistic analysis
retained HLA-B∗57 and HLA-B∗14 as significant predictors
of concomitant anti-TB and ARV drugs induced liver injury.
For HLA-B∗57, the association maintained after correcting for
multiple comparisons (Pc= 0.036).
Associations between HLA-B∗57, HLA-B∗14, and HLA-B∗41
with the pattern and severity of liver toxicity was evaluated by
comparing the proportion of allele carriers between DILI cases
and treatment tolerants (Table 3). Compared with treatment
tolerants, the proportion of HLA-B∗57 allele carriers were
significantly higher in cholestatic and mixed types of DILI.
In addition, the proportion of HLA-B∗14 allele carriers were
higher in the mixed type of DILI cases than the treatment
tolerants. There were no statistically significant differences in
the hepatocellular type of DILI. Compared with treatment
tolerants, the proportion of patients carrying HLA-B∗57 allele
was significantly higher in the mild-to-moderate DILI group, and
those carrying HLA-B∗14 in the severe DILI group were over-
represented. There was a statistically significant difference in the
proportion of HLA-B∗41 allele carriers in the mild-to-moderate
DILI group compared with treatment tolerants.
HLA-B variant alleles that showed significant association
with DILI from the low-resolution genotyping were further
subjected to high resolution (four digit) testing to identify the
sub-variant allele. The result from high resolution genotyping
was interpreted in conjunction with the results from the prior
low-resolution typing. HLA-B∗57 was the only variant allele that
exhibited a significant association with DILI after correcting for
multiple testing. Thus, high-resolution typing was done for all
subjects who were genotyped as carriers of HLA-B∗57 in the
low-resolution typing (see Table 4).
Of all HLA-B∗57 alleles identified, HLA-B∗57:03 accounted
58.3% and HLA-B∗57:02 accounted 41.7%. HLA-B∗57:01 was
not detected. Of the HLA-B∗57 allele carrier cases, 10 (58.8%)
had HLA-B∗57:03 (four homozygous) and the rest seven (41.2%)
had HLA-B∗57:02 (two homozygous). There was only one HLA-
B∗57 allele carrier (heterozygous for HLA-B∗57:02) out of the
46 treatment-tolerants. The proportion of HLA-B∗57:03 and
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TABLE 2 | Comparison of proportion of HLA-B allele carriers between patients who developed ARV and anti-tuberculosis drugs induced liver injury
(cases) and patients who did not (treatment tolerants).




Univariate analysis Multivariate analysis
N (%) N (%) P Pc OR (95% CI) P OR (95% CI)
B*57 17 (37.0%) 1 (2.2%) 0.002 0.036 26.38 (3.33–209.07) 0.002 30.08 (3.44–263.11)
B*14 10 (21.7%) 3 (6.5%) 0.047 0.845 3.98 (1.02–15.58) 0.014 7.51 (1.50–37.68)
B*41 3 (6.5%) 10 (21.7%) 0.047 0.845 0.25 (0.06–0.98) 0.112 0.26 (0.05–1.37)
B*15 8 (17.4%) 16 (34.8%) 0.06 1.000 0.40 (0.15–1.05) 0.526 0.68 (0.21–2.23)
B*08 0 4 (8.7%) 0.12 1.48 (0.01–1.94)*
B*18 0 3 (6.5%) 0.24 0.13 (0.01–2.66)*
B*44 2 (4.3%) 5 (10.9%) 0.25 0.37 (0.07–2.03)
B*13 5 (10.9%) 8 (17.4%) 0.37 0.58 (0.17–1.93)
B*58 4 (8.7%) 2 (4.3%) 0.41 2.10 (0.36–12.05)
B*51 6 (13.0%) 4 (8.7%) 0.50 1.58 (0.41–6.00)
B*53 4 (8.7%) 3 (6.5%) 0.70 1.37 (0.29–6.47)
B*07 10 (21.7%) 9 (19.6%) 0.80 1.14 (0.42–3.14)
B*49 10 (21.7%) 10 (21.7%) 1.00 1.00 (0.37–2.69)
B*35 1 (2.2%) 0 1.00 3.07 (0.12–77.25)*
B*37, *39, *50, *73 0 2 (4.3%) 0.50 0.19 (0.01–4.10)*
*Haldane’s modification.
ARV, Antiretroviral; CI, Confidence Interval; HLA, Human Leukocyte Antigen; OR, Odds ratio; TB, Tuberculosis.
P, P-values were calculated by Fisher’s exact test comparing the positive alleles in cases with those of treatment tolerants.
Pc, Corrected P-values were adjusted by using Bonferroni’s correction for multiple comparisons to account for the observed 18 HLA-B alleles. P-value < 0.05 is highlighted in bold.
TABLE 3 | Association of HLA-B alleles with the pattern and severity of drug-induced liver injury.
Characteristics HLA-B*57 carriers HLA-B*14 carriers HLA-B*41 carriers
N (%) P OR (95% CI) N (%) P OR (95% CI) N (%) P OR (95% CI)
DILI PATTERN
Treatment tolerants (n = 46) 1 (2.2) – – 3 (6.5) – – 10 (21.7) – –
Cholestatic (n = 29) 13 (44.8) 0.001 36.6 (4.4–302.3) 5 (17.2) 0.17 3.0 (0.7–13.6) 2 (6.9) 0.11 0.3 (0.1–1.3)
Hepatocellular (n = 2) 0 1.00 6.1 (0.2–190.1)* 1 (50.0) 0.16 14.3(0.7–29.4) 0 1.00 0.7 (0.1–15.6)*
Mixed (n = 15) 4 (26.7) 0.017 16.4 (1.7–161.3) 4 (26.7) 0.048 5.2 (1.0–26.8) 1 (6.7) 0.22 0.3 (0.1–2.2)
SEVERITY GRADE
Mild-to-moderate (n = 39) 16 (41.0) 0.001 31.3 (3.9–251.0) 7 (17.9) 0.12 3.1(0.8–13.1) 2 (5.1) 0.04 0.2 (0.1–1.0)
Severe (n = 7) 1 (14.3) 0.173 2.7 (0.6–11.7) 3 (42.9) 0.01 10.8 (1.6–71.9) 1 (14.3) 0.65 0.6 (0.1–5.6)
*Haldane’s modification.
CI, Confidence Interval; HLA, Human Leukocyte Antigen; OR, Odds ratio. P-value < 0.05 is highlighted in bold.
B∗57:02 allele carriers were significantly higher in the DILI cases
than treatment tolerants [P = 0.01, OR = 26.8 (1.5–47.2) and P
= 0.03, OR= 8.1 (1.0–68.6)], respectively.
Comparisons of HLA-B∗57, ∗14, and ∗41 (from the low-
resolution genotyping) as well as HLA-B∗57:02 and B∗57:03
(from the high-resolution genotyping) allele frequencies between
DILI cases and treatment tolerants is presented in Table 5. The
overall allele frequency of HLA-B∗57 was higher (13.0%) than
that of the other HLA-B alleles (7.6% for B∗14 and 7.1% for
B∗41). The allele frequency of HLA-B∗57 was higher in DILI
cases (25.0%) compared to treatment tolerants (1.1%). TheHLA-
B∗57:03 and B∗57:02 allele frequencies in DILI cases (15.2 and
9.8%) were higher than the treatment tolerants (0 and 1.1%),
respectively.
DISCUSSION
In the present study, we investigated the association of HLA-
B variant alleles with risk for concomitant anti-TB and ARV
drugs induced liver toxicity. The proportion of HLA-B∗57
allele carriers in Ethiopian patients who developed anti-TB
and ARV drugs induced liver toxicity (37.0%), particularly in
those who developed cholestatic type of liver toxicity (44.8%)
was significantly higher compared with those who tolerated the
treatment (2.2%). The proportion of HLA-B∗14 allele carriers
who developed DILI (21.7%) was also significantly higher
compared with the treatment tolerants (6.5%). These indicate
that HLA-B∗57 and B∗14 allele carriers might be at a higher risk
of developing anti-TB and ARV drugs co-treatment induced liver
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toxicity. Accordingly, these variant alleles might play important
roles in the pathogenesis of immune-mediated liver toxicity
during anti-TB and ARV drugs co-treatment. TheHLA-B∗57 and
B∗14 molecules may function as endogenous antigen presenting
molecules for the drugs/metabolites to HLA-restricted cytotoxic
T-cell activation (Pichler, 2002). To our knowledge, this is the first
report to investigate the association ofHLA-B∗57, B∗14, and B∗41
alleles with anti-TB and ARV drugs co-treatment induced liver
toxicity.
The HLA-B∗57 variant allele, which was observed in
significantly higher proportion among DILI cases than treatment
tolerants, had a high specificity (97.8%) and positive predictive
value (94.4%). Hence, HLA-B∗57 is likely to be an important
predictor for anti-TB and ARV drugs co-treatment induced
liver injury. However, there could be additional yet unidentified
genetic markers and non-genetic risk factors involved in the
TABLE 4 | High resolution genotyping data for all HLA-B*57 allele carriers
stratified by DILI type.
Patient No. Age Sex Status DILI type Allele 1 Allele 2
1 25 F Case Cholestatic B*57:03 B*57:03
2 34 F Case Cholestatic B*57:03 B*57:03
3 45 M Case Cholestatic B*57:03 B*57:03
4 25 M Case Cholestatic B*57:02 B*57:02
5 28 F Case Cholestatic B*57:03 B*58:01
6 37 F Case Cholestatic B*57:02 B*51:08
7 28 F Case Cholestatic B*57:03 B*49:01
8 55 M Case Cholestatic B*57:02 B*39:12
9 45 F Case Cholestatic B*57:02 B*58:01
10 30 F Case Cholestatic B*57:03 B*53:01
11 60 M Case Cholestatic B*57:03 B*13:02
12 30 F Case Cholestatic B*57:03 B*53:01
13 30 F Case Cholestatic B*57:02 B*44:02
14 30 F Case Mixed B*57:03 B*57:03
15 31 M Case Mixed B*57:02 B*57:02
16 49 M Case Mixed B*57:03 B*58:01
17 38 F Case Mixed B*57:02 B*49:01
18 32 F Control Treatment tolerant B*57:02 B*41:02
DILI, Drug induced liver injury. B*57:02 and B*57:03 alleles are highlighted in bold.
pathogenesis of DILI. The matched case-control design used in
this study minimizes effects of potential confounders and may
increase power to identify genetic associations. Although this
limits us from exploring associations of the matching variables
such as sex, body mass index, Karnofsky score, CD4 count,
and HIV viral load which were independently and significantly
associated with the risk of developing DILI (Yimer et al., 2011,
2014). Association of CD4 cell counts and Karnofsky score as risk
factors for DILI were also found in this study, although the others
were not significant.
Studies suggest that a particular HLA-B allele may exert
a protective effect against certain adverse drug reactions as
evidenced by lower allele carrier frequencies in cases compared
with treatment tolerants. HLA-DQA1∗01:02 was identified as
a protective variant for anti-TB drugs induced hepatotoxicity
(Sharma et al., 2002). HLA-B∗40:01 and HLA-B∗07:02 were also
identified as protective variant alleles for carbamazepine-induced
severe cutaneous adverse reactions (Alfirevic et al., 2006; Hung
et al., 2006). In our study, statistically significant lower allele
carrier rate of HLA-B∗41 was noted in the DILI cases compared
with the treatment tolerants (6.5 vs. 21.7%), but this effect did
not reach statistical significance after correcting for multiple
comparisons. Further, analysis is required to clarify the role of
HLA-B∗41 in the prevention of development of anti-TB and ARV
drugs co-treatment induced liver injury.
Our result indicated a positive association of HLA-B∗57 allele
with mild-to-moderate liver injury and the HLA-B∗14 allele
with severe liver injury. On the other hand, HLA-B∗41 allele
was negatively associated with mild-to-moderate liver injury.
Accordingly, the association of HLA-B alleles with anti-TB and
ARV drugs co-treatment induced liver injury may seem to
depend on the severity of liver injury. The HLA-B∗57 allele may
be critical for the initiation of the immune response to cause DILI
and the HLA-B∗14 allele for the progression to severe degree of
liver injury. On the other hand, the HLA-B∗41 allele seems to
play a role in the prevention of development of mild-to-moderate
liver injury due to anti-TB and ARV drugs co-treatment. These
findings warrant further investigation in a larger DILI case
samples for each severity grade of liver injury.
DILI can be hepatocellular (predominant rise in ALT),
cholestatic (predominant rise in ALP), or mixed type liver
injury (Hussaini and Farrington, 2014). Recently, we conducted
TABLE 5 | Comparison of HLA-B allele frequencies distribution between patients who developed ARV and anti-tuberculosis drugs induced liver toxicity
(cases) and patients who did not (treatment tolerants).





Observed frequency 95% CI Observed frequency 95% CI OR 95% CI
HLA-B*57 0.250 0.162–0.338 0.011 0.004–0.032 <0.001 30.33 4.00–230.3
HLA-B*14 0.130 0.062–0.199 0.033 0.004–0.069 0.06 3.30 1.02–10.65
HLA-B*41 0.033 0.004–9.069 0.109 0.045–0.172 0.08 0.28 0.07–1.04
HLA-B*57:03 0.152 0.079–0.226 0 0
HLA-B*57:02 0.098 0.037–0.159 0.011 0.001–0.032
OR, Odds Ratio; CI, Confidence interval; HLA, Human leukocyte antigen.
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a prospective observational study to evaluate the incidence,
type, severity, and predisposing risk factors for DILI in a large
well-defined TB and/or HIV patient cohort receiving either
anti-TB drugs alone, ARV drugs alone or concomitant anti-
TB and ARV therapy (Yimer et al., 2014). We found rates of
hepatocellular DILI being highest among patients treated with
anti-TB drugs alone than patients treated with ARV drugs alone
or co-treated with anti-TB drugs. On the other hand, the rates
of cholestatic DILI was highest among patients treated with
efavirenz based-ARV drugs alone than patients treated with anti-
TB drugs alone or with ARV drugs (Yimer et al., 2014). DILI due
to anti-TB drugs in TB mono-infected patients is known to be
more of hepatocellular type. In the present study, most of the
TB-HIV co-infected patients treated with concomitant anti-TB
and efavirenz based-ARV drugs developed cholestatic DILI cases.
Apparently, there is a significant contribution from efavirenz
based-ARV drugs toward developing cholestatic type of DILI.
Indeed, the significant association of HLA-B∗57 variant allele
with cholestatic type DILI identified in the present study might
reflect for ARV-drugs induced hepatotoxicity. However, the role
of HLA variant alleles for predisposition to anti-TB DILI cannot
be ruled out (Sharma et al., 2002; Chen et al., 2015). Further,
studies are necessary to investigate the association of HLA allele
carrier status with anti-TB drugs alone as well as ARV drugs
alone-induced liver injury.
Major histocompatibility complex (MHC) class I and class
II-mediated immunological reactions are implicated in DILI,
particularly in the cholestatic type that involves damage to the
biliary system (Andrade et al., 2004; Daly, 2010). In line with
this, carrier status of HLA-B∗57 was significantly higher in
patients who presented with the cholestatic type of DILI (44.8%)
and mixed type (26.7%) compared with those who tolerated
the treatment (2.2%). None of the patients who developed
hepatocellular DILI were carriers of HLA-B∗57 variant allele.
HLA-B∗57 allele is associated with long-term non-progressive
chronic HIV-1 infection by restricting cytotoxic T-lymphocyte
response (Goulder et al., 2000). HLA-B∗57:01 and B∗57:03 are
the most prevalentHLA-B∗57 subtypes in Caucasian and African
populations, respectively (Pelak et al., 2010; Apps et al., 2013).
The HLA-B∗57:01 and B∗57:03 alleles are protective against HIV
disease progression, and appear to present identical Gag epitopes
(Payne et al., 2014). HLA-B∗57:01, B∗57:02, and B∗57:03 share
more than 90% sequence homology and as such have peptide-
binding repertoires which substantially overlap (Illing et al.,
2012; Ogese et al., 2017). Although in ART naïve patients HLA-
B∗57 (B∗57:01 in Europe and US, B∗57:03 in black Africans)
confers protective effect against HIV-1 disease progression to
AIDS (Costello et al., 1999; Migueles et al., 2000; López-Larrea
et al., 2005; Frater et al., 2007), it may exert contradictory effect
on treatment outcome when the disease course is altered by
ARV therapy (Dold et al., 2015). Previous studies reported the
association of HLA-B∗57 with increased all causes of mortality
(Dold et al., 2015) and reduced virological responses during
ARV therapy (Kuniholm et al., 2011). HLA-B∗57 allele is also
known to be associated with immune-mediated drug-induced
hypersensitivity reactions. Carriers of HLA-B∗57:01 allele are
at higher risk of developing abacavir-induced hypersensitivity
reactions (Hetherington et al., 2002), whereas HLA-B∗57:03 is
associated with spondylarthropathies (López-Larrea et al., 2005).
Indeed, genetic screening forHLA-B∗57:01 variant allele has been
shown to reduce drug toxicity and subsequently led to a labeled
recommendation of routine screening before treatment initiation
(Hughes et al., 2008; Mallal et al., 2008).
The frequency and subtypes of HLA-B∗57 variant alleles
display wide inter-ethnic variability globally ranging from 0 to
22.5% (http://www.allelefrequencies.net/). The overall frequency
of HLA-B∗57 in our study population from Ethiopia is 13%
which is relatively high. HLA-B∗57:01 occurs in Asians and
Caucasians (up to 5%). The HLA-B∗57:03 and B∗57:02 variant
alleles commonly occur in black population reaching up to 3 and
7% allele frequencies, respectively. Interestingly HLA-B∗57:01
was not detected, and it may be rare or absent in Ethiopians
similar to other black Africans where the allele frequency is
<1%. The overall HLA-B∗57:03 and B∗57:02 allele frequencies
in our TB/HIV co-infected study population was 7.6 and 5.4%,
respectively, although the frequencies in healthy Ethiopians is
yet unknown. Interestingly, HLA-B∗57:03 and B∗57:02 allele
frequencies in DILI cases (15.2 and 9.8%) were significantly
higher than the allele frequencies in the treatment-tolerants (0
and 1.1%), respectively.
There were some limitations in this study. First, as DILI is
a rare event, it was not easy to get large number of cases (four
years were required to collect the DILI cases in this study), which
subsequently resulted in a small number of samples for sub-group
analysis. The second limitation is that as drug combinations are
the current treatment protocols for TB and HIV co-infections,
and hence we cannot link the risk variant allele to a specific drug
or class of drug(s). Since first line anti-TB and HIV treatment
regimen consists of combination therapy, it is not possible to
study individual drug-induced liver toxicity in TB and HIV
co-infected patients for ethical reasons. However, our study
represents an important first step in applying HLA-B typing to
identify genetic variants for anti-TB and ARV drugs co-treatment
induced liver injury.
Identification of genetic risk factors for anti-TB, and ARV
drugs co-treatment induced liver injury is essential for patient
safety. The HLA risk alleles predisposing to immune-mediated
anti-TB and ARV drugs induced liver toxicity in black African
population are not well investigated. A common problem
encountered in HLA genotyping is inability to determine the
variant alleles accurately using a simple genotyping procedure.
This is mainly due to the extensive genetic diversity in HLA
gene locus. Accurate allele-level HLA typing using the current
methods requires high workload, cost and time. Because of
extreme genetic variation of the HLA locus, pharmacogenetic
testing for routine clinical practice is increasingly challenging in
resource limited settings. However, the recent development of
second-generation sequencing methods provides the possibility
of sequencing a single DNA strand in isolation. Establishing a
straightforward and affordable genotyping method for accurate
HLA typing to identify patients at risk of developing drug-
induced adverse events may lay the ground for the future
application of pharmacogenetic testing in clinical practice for
globalized personalized medicine.
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In conclusion, HLA-B variant alleles may play important
roles in determining the risk and severity of concomitant anti-
TB and ARV drugs induced liver toxicity. HLA-B∗57 variant
alleles (HLA-B∗57:03 and HLA-B∗57:02) are risk factors to
develop anti-TB and ARV drugs co-treatment induced liver
injury, mainly of cholestatic type and mild DILI cases. The
possible risk association of HLA-B∗14 allele with severe DILI
and the protective association of HLA-B∗41 require further
investigations. Additional studies are necessary to understand the
roles of the identifiedHLA-B variant alleles in the pathogenesis of
anti-TB and ARV drugs co-treatment induced liver toxicity.
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